Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.

Shanmugapriya ThangavadivelQiuhong ZhaoNarendranath EpperlaLindsey RikeXiaokui MoMohamed BadawiDarlene M BystryMitch A PhelpsLeslie A AndritsosKerry A RogersJeffrey JonesJennifer A WoyachJohn C ByrdFarrukh T Awan

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Lenalidomide is efficacious with manageable toxicities as an early intervention strategy in patients with high-risk CLL, but did not enhance humoral response to PCV13 vaccine.

Keyphrases

chronic lymphocytic leukemia
randomized controlled trial
immune response
multiple myeloma
low dose
high dose